O'Leary's Bullish on DeFi
Looking to invest into DeFi? Kevin O'Leary's stock pick could be the way to go.
Read more.

INM Insider Trading (InMed Pharmaceuticals)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): $28,800.00
Insider Selling (Last 12 Months): $0.00

InMed Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at InMed Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

InMed Pharmaceuticals Share Price & Price History

Current Price: $1.50
Price Change: Price Decrease of -0.09 (-5.66%)
As of 10/27/2021 01:00 AM ET

This chart shows the closing price history over time for INM up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Is this Seattle Penny Pot Stock a Potential Blockbuster?
A small, rapidly expanding Seattle cannabis company is gaining attention from investors. Founded by two cannabis veterans, the company has increased sales 8-fold and is looking to double sales again in the next two years. Now selling for less than $1 per share, this is an opportunity to acquire thousands of shares – a potential windfall.
Get Free Report on #1 Cannabis Pick for 2021

InMed Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/28/2021Bruce ColwillCFOBuy5,000$1.77$8,850.00View SEC Filing Icon  
9/28/2021Eric A AdamsCEOBuy11,400$1.75$19,950.00View SEC Filing Icon  
See Full Table
Insider Buying at InMed Pharmaceuticals?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for InMed Pharmaceuticals and related companies.

SEC Filings (Institutional Ownership Changes) for InMed Pharmaceuticals (NASDAQ:INM)

13.19% of InMed Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at INM by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

InMed Pharmaceuticals Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
8/17/2021Armistice Capital LLC890,000$2.83M0.1%+278.7%9.954%Search for SEC Filing on Google Icon
8/12/2021Penserra Capital Management LLC19,912$49K0.0%N/A0.223%Search for SEC Filing on Google Icon
5/21/2021Citadel Advisors LLC17,211$57K0.0%N/A0.214%Search for SEC Filing on Google Icon
5/18/2021Morgan Stanley12,581$41K0.0%+76.6%0.156%Search for SEC Filing on Google Icon
5/18/2021Citadel Advisors LLC17,211$57K0.0%N/A0.214%Search for SEC Filing on Google Icon
5/17/2021Armistice Capital LLC235,000$0.78M0.0%N/A2.919%Search for SEC Filing on Google Icon
1/29/2021Creative Planning10,990$36K0.0%N/A0.157%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
InMed Pharmaceuticals logo
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.
Read More on InMed Pharmaceuticals

Today's Range

Now: $1.50
Low: $1.49
High: $1.61

50 Day Range

MA: $1.99
Low: $1.40
High: $2.51

52 Week Range

Now: $1.50
Low: $1.38
High: $8.94

Volume

499,975 shs

Average Volume

246,718 shs

Market Capitalization

$14.07 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of InMed Pharmaceuticals?

InMed Pharmaceuticals' top insider investors include:
  1. Bruce Colwill (CFO)
  2. Eric A Adams (CEO)
Crisis Of Low Supply, High Demand Means Big Opportunity
Right now helium is one of world's best investments. It's Earth's most nonrenewable resource and it's fast running out. That's a crisis because helium is a critical in medical diagnostics, military weapons, and semiconductors, which are the chips that run all the 21st century's gadgets, appliances, and vehicles.
Get a free report that shows you how its supply